CellBion Co., Ltd. (KOSDAQ:308430)

South Korea · Delayed Price · Currency is KRW

15,000

+260 (1.76%)

At close: Aug 14, 2026

-46.52% (1Y)

Market Cap	193.58B -46.2%
Revenue (ttm)	2.15B -18.4%
Net Income	7.75B
EPS	n/a
Shares Out	12.91M
PE Ratio	24.98
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,431
Open	15,250
Previous Close	14,740
Day's Range	14,710 - 15,420
52-Week Range	9,930 - 42,200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos... [Read more]

Industry Pharmaceutical Preparations

Founded 2010

Employees 55

Stock Exchange KOSDAQ

Ticker Symbol 308430

Full Company Profile

Financial Performance

In 2025, CellBion's revenue was 1.95 billion, a decrease of -15.05% compared to the previous year's 2.29 billion. Losses were -7.57 billion, 4.23% more than in 2024.

Financial Statements